Chargement en cours...
Phase I Study of Pasireotide (SOM 230) and Everolimus (RAD001) in Advanced Neuroendocrine Tumors
Octreotide and everolimus have demonstrated efficacy in neuroendocrine tumors. Pasireotide is a somatostatin analog with binding affinity to a broader range of somatostatin receptor subtypes than octreotide. We performed a phase I study to evaluate the safety and feasibility of combining pasireotide...
Enregistré dans:
| Publié dans: | Endocr Relat Cancer |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4469068/ https://ncbi.nlm.nih.gov/pubmed/22736724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-11-0382 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|